Affiliation:The Chinese academy of engineering Chinese academy of medical sciences
Dr. Liu Gengtao has worked with the Department of Pharmacology of the Institute of Materia Medica of the Chinese Academy of Medical Sciences since his graduation from the Hunan Medical College in 1956. He once studied in France, Japan and USA as a visiting scholar or a collaborator. In the last 30 years or so, he has mainly devoted himself to the research on and development of new drugs from traditional Chinese medicine and synthetic compounds. Based on the study of traditional Chinese medicine, Fructus Schizandra (五味子), he successfully created two novel drugs for the treatment of chronic viral hepatitis. One of them is DDB, which has been widely used for therapy of viral hepatitis for more than 20 years in China, and has been exported to Korea, Egypt, Indonesia and Viet Nam in the past few years. Another one is called Bicyclol, which obtained the license for the manufacture and sale in China in 2002, and is protected by patent in 15 developed countries. He also developed Ganoderma spores (灵芝孢子粉) injection to treat several neuromuscular diseases which are difficult to treat with Western drugs. Recently he has focused on the study of novel drugs for the treatment of Parkinson’s disease and Alzheimer disease, and reversal agent of multi-drug resistance (MDR) to cancer chemotherapy. Two leading compounds from traditional Chinese herbs have been found. He is author and co-author of 170 papers and 15 patents, and serves as editor for 10 national and international journals. He won eight awards by the Chinese Government, the Ministry of Health and Beijing Municipality due to his outstanding achievements in the research on pharmacology and innovation of novel drugs.